Figure 4From: MicroRNAs induced in melanoma treated with combination targeted therapy of Temsirolimus and BevacizumabClustering analysis of miRNA expression according to clinical outcome and BRAF tumor status. The heat map illustrates the result of the two-way hierarchical clustering of pre-selected miRNAs and samples. The color scale illustrates the relative expression level or changes in expression level across all samples: red color represents an expression level above the mean and blue color represents expression lower than the mean. Patients #5, 7, and 8 had progressive disease (PD), patient #6 and 9 had partial responses (PR), and the remaining patients had stable disease (SD). (A) Clustering was performed with pre-treatment expression values (LMRs) for miRNAs with t-test p-value < 0.01 and effect size > 0.5. (B) Clustering was performed with changes in miRNA expression (dLMRs) with combination treatment for miRNAs whose t-test p-value < 0.04 and effect size > 0.5. (C) Clustering was performed with pre-treatment expression values (LMRs) for miRNAs whose t-test p-value < 0.02 and effect size > 0.5, using p-values obtained from two-tailed t-tests comparing the average expression level for patients with BRAF mutant melanomas (in orange) with those who had wild-type BRAF melanomas.Back to article page